Human Interleukin-6 ELISA Assay Kit - high sensitivity
For affordable and efficient research
Interleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in the body´s response to tissue injury or infection. Il-6 is produced by various cells, including T-cells, B-cells, macrophages, as well as vascular endothelial cells, mast cells, and dentritic cells (1). Il-6 secretion is stimulated during inflammatory response and travels through the bloodstream to the liver, where it induces the production of acute phase reactants such as C-reactive protein and others (1).
Human Interleukin-6 ELISA Assay Kit – high sensitivity
BIOMEDICA´s human Interleukin-6 (IL-6) ELISA Assay is highly sensitive and shows detectable values in serum and in plasma samples.
Features & Benefits
- High Specificity – using characterized epitope-mapped antibodies
- High Sensitivity – measurable values in both serum and plasma
- Superior Quality – validated according to international quality guidelines
- Standardized – use of WHO intern.standards for kit calibration & harmonization
- User-Friendly – ready to use color coded prediluted standards & controls
Take 15% off the human IL-6 ELISA Assay now through end of 2024!
Use Promotion Code: BCIL62024 on your order.
Human IL-6 ELISA Kit (cat. no. BI-IL6)
- Method: Sandwich ELISA, HRP/TMB, 12×8-well detachable strips
- Sensitivity LOD: 0.28 pg/ml (measurable concentrations in serum AND plasma samples!)
- Sample types: human serum, plasma (EDTA, citrate, heparin), cell culture supernatants, urine)
- Sample volume: 100 µl/well
- Dynamic range: 0 – 200 pg/ml (0 / 3.12 / 6.25 / 12.5 / 25/ 50 / 100 / 200)
- Time to result: 4.5 hours
- Specificity: Endogenous and recombinant human IL-6
- Protokol booklet
- Validation data file
- Alternative name: Interleukin-6
Clinical significance of Interleukin-6
- Inflammatory diseases: elevated IL-6 levels are detected in various inflammatory conditions such as rheumatoid arthritis (2), systemic lupus erythematosus (3) , and inflammatory bowel disease (4). Therapies targeting Il-6 have been already approved (5).
- Cancer: Il-6 is abundantly present in the tumor microenvironment of various tumours. It promotes tumnorigenesis, invasiveness, and metastases in cancer (6). New perspectives in cancer immunotherapy targeting IL-6 are discussed (7).
- Metabolic diseases: Dysregulated IL-6 activity is associated with pathologies involving chronic inflammation and autoimmunity including metabolic diseases like obesity, metabolic syndrome or type-2 diabetes (8).
RELATED BIOMEDICA KITS
Human VEGF ELISA (BI-VEGF), Human Angiopoietin-2 ELISA (BI-ANG2)
LITERATURE
- Interleukin 6: at the interface of human health and disease. Grebenciucova E, VanHaerents S. Front Immunol. 2023 Sep 28;14:1255533. doi: 10.3389/fimmu.2023.1255533. PMID: 37841263; PMCID: PMC10569068.
- Interleukin-6 in Rheumatoid Arthritis. Pandolfi F, Franza L, Carusi V, Altamura S, Andriollo G, Nucera E. Int J Mol Sci. 2020 Jul 23;21(15):5238. doi: 10.3390/ijms21155238. PMID: 32718086; PMCID: PMC7432115.
- Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus. Nepal D, Gazeley D. Rheumatology (Oxford). 2023 Dec 1;62(12):3804-3810. doi: 10.1093/rheumatology/kead416. PMID: 37594751.
- Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel disease. Garbers C, Lokau J. Expert Opin Ther Targets. 2024 Jan-Feb;28(1-2):57-65. doi: 10.1080/14728222.2024.2306341. Epub 2024 Jan 23. PMID: 38217849.
- Therapeutic uses of anti-interleukin-6 receptor antibody. Kang S, Tanaka T, Kishimoto T. Int Immunol. 2015 Jan;27(1):21-9. doi: 10.1093/intimm/dxu081. Epub 2014 Aug 20. PMID: 25142313.
- The Role of IL-6 in Cancer Cell Invasiveness and Metastasis-Overview and Therapeutic Opportunities. Rašková M, Lacina L, Kejík Z, Venhauerová A, Skaličková M, Kolář M, Jakubek M, Rosel D, Smetana K Jr, Brábek J. Cells. 2022 Nov 21;11(22):3698. doi: 10.3390/cells11223698. PMID: 36429126; PMCID: PMC9688109.
- New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM.J Immunother Cancer. 2023 Nov;11(11):e007530. doi: 10.1136/jitc-2023-007530. PMID: 37945321; PMCID: PMC10649711.
- IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases. Zhao J, Turpin-Nolan S, Febbraio MA. Cytokine. 2021 Aug;144:155549. doi: 10.1016/j.cyto.2021.155549. Epub 2021 May 4. PMID: 33962843.